Lundbeck Q3 2019 Financial Results

Rexulti shows significant growth driven by demand - roll-out in new markets continues 7 Rexulti sales* (Quarterly DKKm) +30% 1.800 Grew 35% (27% in L.C.) to DKK 1,620 million in 9M 2019 I 600 * In the U.S., volume is up 22% y/y in Q3¹) North America Other regions Launched in North America, selected European markets and Australia, Chile, Mexico and Saudi Arabia Phase III programme in PTSD²) commenced in October 2019 * Phase II study in BPD³) commenced in October 2019 1) Symphony Health (cf. Bloomberg) 2) Borderline Personality Disorder. 3) Post-Traumatic Stress Disorder 400 200- Q3.17 Q3.18 Q3.19 1.500 1.200 900 600 300 *) Lundbeck's share of revenue Rexulti sales* (9M - DKKM) +35% 9M.17 9M.18 9M.19 Lundbeck

View entire presentation